DAN COPELAND, MBAchief executive officer D an was the founder and president of Emerge Life Sciences, a consulting company focused on new and emerging technologies in the life science space with significant work in translational medicine and devices over the last decade. Prior to this, he focused on commercialization of respiratory products for asthma and COPD with GSK.    

CAROLYN DURHAM, PhDchief scientific officer



C arolyn received a PhD in Mucosal Immunology and was a Howard Hughes Fellow in Translational Medicine. She was the Scientific Advisor of Montague Capital, focusing on scientific strategy and collaboration. She has spearheaded the transition of Arina-1 from 15 years of research to product commercialization.